Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.64 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.64 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.50 |
| ▸ | KHK | P50053 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.36 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29724139 | 1.00 | CSNK1A1 (0.64) | CSNK1A1CLK4PIN1KHKALDH1A1 | |
| SCHEMBL12765591 | 0.78 | CSNK1A1 (0.46) | CSNK1A1CLK4PIN1KHKALDH1A1 | |
| SCHEMBL19100200 | 0.78 | CSNK1A1 (0.60) | CSNK1A1CLK4PIN1KHKALDH1A1 | |
| SCHEMBL1143429 | 0.78 | CSNK1A1 (1.00) | CSNK1A1CLK4PIN1KHKALDH1A1 | |
| SCHEMBL3356613 | 0.78 | CSNK1A1 (0.55) | CSNK1A1CLK4PIN1KHKALDH1A1 | |
| SCHEMBL24135156 | 0.78 | CSNK1A1 (0.60) | CSNK1A1CLK4PIN1ALDH1A1NPSR1 | |
| SCHEMBL12726137 | 0.78 | CSNK1A1 (0.46) | CSNK1A1CLK4PIN1KHKALDH1A1 | |
| SCHEMBL3595385 | 0.77 | CSNK1A1 (0.44) | CSNK1A1CLK4PIN1 | |
| SCHEMBL14667068 | 0.77 | CSNK1A1 (0.44) | CSNK1A1CLK4PIN1 | |
| SCHEMBL4773544 | 0.74 | CSNK1A1 (0.55) | CSNK1A1CLK4PIN1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 855 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431324-A | 1- (4/5-Cyano-6-substituted pyrimidine-2-yl) -1H-pyrazole-4-formic acid compound, and preparation method and application thereof | 沈阳药科大学 | 2025-02-14 | — | — | CN | claimed |
| EP-3279998-B1 | NON-AQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG CHEMICAL LTD (KR) | 2022-01-12 | — | — | EP | claimed |
| CN-112592318-A | 2- (4-methionyl) anilino-4-aminopyrimidine derivatives and application thereof | 贵州医科大学 | 2021-04-02 | — | — | CN | claimed |
| CN-107431197-B | Non-aqueous electrolyte and lithium secondary battery comprising same | 株式会社LG化学 | 2020-08-21 | — | — | CN | claimed |
| US-10193182-B2 | Non-aqueous electrolyte and lithium secondary battery comprising same | LG CHEM, LTD. (KR) | 2019-01-29 | — | — | US | claimed |
| CN-108178748-A | The synthetic method of 4,6- dichloro pyrimidine -5- formonitrile HCNs | 和记黄埔医药（上海）有限公司 | 2018-06-19 | — | — | CN | claimed |
| EP-3279998-A1 | NON-AQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG Chem, Ltd. (KR) | 2018-02-07 | — | — | EP | claimed |
| US-20180013168-A1 | NON-AQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-01-11 | — | — | US | claimed |
| CN-104610254-A | Low-cost preparation method for palbociclib | XINFA PHARMACEUTICAL CO LTD | 2015-05-13 | — | — | CN | claimed |
| CN-122094954-A | Tricyclic quinolones and 1, 8-naphthyridin-2-one BCL6 difunctional degrading agents | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| US-20260138974-A1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | LEUKOS BIOTECH S L (ES) | 2026-05-21 | — | — | US | disclosed |
| US-12630549-B2 | Pyrazoleamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | disclosed |
| WO-2003076708-A1 | TEXTILE MATERIALS PROVIDED WITH CALIXARENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF | DEUTSCHES TEXTILFORSCHUNGSZENTRUM NORD-WEST E.V. (DE) | 2003-09-18 | — | — | WO | disclosed |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | disclosed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003032997-A1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-24 | — | — | WO | disclosed |
| EP-0611259-B1 | Fibre-reactive phthalocyanine dyes | CLARIANT FINANCE BVI LTD (VG) | 1998-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138974-A1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | HTR3B, HTR1B, HTR1A | CSNK1A1 1540/4885CLK4 3848/4885PIN1 4861/4885 |
| US-20040029902-A1 | Antiinflamamtory agents | FCER2, FCGR1A, HNMT | CSNK1A1 3375/4885CLK4 4737/4885PIN1 4276/4885 |
| US-20180013168-A1 | NON-AQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | WEE1, CLCN2, SLC26A3 | CSNK1A1 2701/4885CLK4 24/4885PIN1 2646/4885 |
| US-12630549-B2 | Pyrazoleamide derivatives | CYP11B2, CYP11B1, ADRA1B | CSNK1A1 144/4885CLK4 2325/4885PIN1 3375/4885 |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | COL1A1, MKI67, INSR | CSNK1A1 1040/4885CLK4 4171/4885PIN1 1488/4885 |
| US-10193182-B2 | Non-aqueous electrolyte and lithium secondary battery comprising same | WEE1, CLCN2, SLC26A3 | CSNK1A1 2701/4885CLK4 24/4885PIN1 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.